SCHEMBL8514231

SCHEMBL8514231

FC(F)(F)c1ccc2sc(N3CCNCC3)nc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN4A P35499 2/20 0.57
SCN9A Q15858 2/20 0.57
ADRB2 P07550 1/20 0.51
NCF1 P14598 1/20 0.51
HTR1D P28221 2/20 0.49
HTR2C P28335 2/20 0.49
ADRB1 P08588 2/20 0.48
HTR6 P50406 1/20 0.47
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
ILK Q13418 2/20 0.43
DYRK1A Q13627 1/20 0.43
IDH2 P48735 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2710713 0.89 SCN4A (0.67) SCN4ASCN9AADRB2NCF1HTR1D
SCHEMBL10219273 0.85 SCN4A (0.62) SCN4ASCN9AADRB2NCF1HTR1D
SCHEMBL17275047 0.82 RAB9A (0.58) SCN4ASCN9AHTR6ALDH1A1MAPT
SCHEMBL20600096 0.79 SCN4A (0.51) SCN4ASCN9AADRB2HTR2CADRB1
SCHEMBL4056087 0.79 NPC1 (0.57) SCN4ASCN9AADRB2NCF1HTR6
SCHEMBL8039956 0.79 AR (0.55) SCN4ASCN9AHTR6ALDH1A1MAPT
SCHEMBL23657771 0.79 RAB9A (0.59) MAPTDYRK1ANPC1RAB9APPARG
SCHEMBL10219374 0.77 SCN4A (0.56) SCN4ASCN9AADRB2HTR6ALDH1A1
SCHEMBL20274141 0.77 RAB9A (0.52) MAPTDYRK1ANPC1RAB9APPARG
SCHEMBL2708421 0.77 DPP4 (0.49) SCN4ASCN9AHTR6ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3145925-B1 ANTHELMINTIC COMPOUNDS BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) 2020-11-04 EP disclosed
EP-3145925-B1 ANTHELMINTIC COMPOUNDS BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) 2020-11-04 EP disclosed
CN-106536518-B Anthelmintic compounds 勃林格殷格翰动物保健美国公司 2020-05-12 CN disclosed
US-10463661-B2 Anthelmintic compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2019-11-05 US disclosed
US-10463661-B2 Anthelmintic compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2019-11-05 US disclosed
US-20180338972-A1 ANTHELMINTIC COMPOUNDS MERIAL INC. (US) 2018-11-29 US disclosed
US-20170100394-A1 ANTHELMINTIC COMPOUNDS MERIAL INC. (US) 2017-04-13 US disclosed
EP-3145925-A1 ANTHELMINTIC COMPOUNDS Merial, Inc. (US) 2017-03-29 EP disclosed
WO-2015179414-A1 ANTHELMINTIC COMPOUNDS MERIAL, INC. (US) 2015-11-26 WO disclosed
WO-2015179414-A1 ANTHELMINTIC COMPOUNDS MERIAL, INC. (US) 2015-11-26 WO disclosed
US-20140357624-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY PF MEDICAMENT (FR) 2014-12-04 US disclosed
US-20140357624-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY PF MEDICAMENT (FR) 2014-12-04 US disclosed
US-8846930-B2 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy PIERRE FABRE MEDICAMENT (FR) 2014-09-30 US disclosed
US-8846930-B2 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy PIERRE FABRE MEDICAMENT (FR) 2014-09-30 US disclosed
US-8846930-B2 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy PIERRE FABRE MEDICAMENT (FR) 2014-09-30 US disclosed
EP-2643318-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY Pierre Fabre Médicament (FR) 2013-10-02 EP disclosed
US-20130172326-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY PIERRE FABRE MEDICAMENT (FR) 2013-07-04 US disclosed
US-20130172326-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY PIERRE FABRE MEDICAMENT (FR) 2013-07-04 US disclosed
US-20130172326-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY PIERRE FABRE MEDICAMENT (FR) 2013-07-04 US disclosed
WO-2012069503-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY PIERRE FABRE MEDICAMENT (FR) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172326-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY KCNA4, KCNA1, KCNB1 SCN4A 42/4885SCN9A 78/4885ADRB2 476/4885
US-10463661-B2 Anthelmintic compounds HRH4, QTRT1, Q6ZSR9 SCN4A 844/4885SCN9A 1170/4885ADRB2 2002/4885
US-20180338972-A1 ANTHELMINTIC COMPOUNDS HRH4, QTRT1, Q6ZSR9 SCN4A 844/4885SCN9A 1170/4885ADRB2 2002/4885
US-20140357624-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY KCNA4, KCNA1, KCNB1 SCN4A 42/4885SCN9A 78/4885ADRB2 476/4885
US-20170100394-A1 ANTHELMINTIC COMPOUNDS HRH4, QTRT1, Q6ZSR9 SCN4A 844/4885SCN9A 1170/4885ADRB2 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.